Analysis: FDC Limited

What does FDC Limited do?

• FDC Limited is a pharmaceutical company with a legacy since 1936, serving over 50 countries.
• The company focuses on anti-diabetics, cardiovascular, gastroenterology, nutraceuticals, and pediatrics.
• Amalgamated with Megasoft Ltd in April 2024, enhancing its presence in hydration therapies and pediatric formulations.

• Product portfolio: Anti-diabetics, cardiovascular, gastroenterology, nutraceuticals, pediatrics, and ophthalmics.
• Export formulations and APIs (Active Pharmaceutical Ingredients) with a focus on US and emerging markets.
• Expanded into dermatology (Zocon division) and nutraceuticals (Nutrica division) in recent years.

Growth thesis

FDC Ltd is an Indian pharma formulator producing essential medicines like Electral (ORS), Zifi antibiotics, and Vitcofol vitamins, with domestic formulations, export formulations, and APIs as core revenue streams. Key growth drivers include 31% H1FY24 export formulation growth (targeting Rs 450-500 Cr by FY25), geographic expansion in underpenetrated East India and West Bengal, and capex of ~INR170 Cr for plant upgrades and R&D to boost margins. Over 2-3 years, the business could achieve stable revenue growth (15-18% CAGR) and EBITDA margin normalization (~19%) as raw material costs stabilize, but margin expansion hinges on successful cost optimization and pricing power in price-controlled domestic segments. Key execution risks include raw material inflation, regulatory delays in US ophthalmic markets, and execution of geographic expansion plans.

Why is FDC Limited stock rising?

• Consolidate field force over next six months, then review
• Improve sales productivity per medical representative (PCPM)
• Expand export footprint into Europe, Asia-Pacific, and African markets
• Build on US ophthalmic business as a key strength
• Continue R&D investments in ANDA filings and clinical studies for US and other ROW markets

Research report

companyname: FDC Limited ticker: FDC sector: Pharmaceuticals FDC Limited is an Indian pharmaceutical company founded in 1940 that manufactures and markets branded generic formulations, active pharmaceutical ingredients (APIs), and functional foods. It operates nine manufacturing plants across India (Roha, Waluj, Sinnar, Goa I/II/III, Baddi) and sells products in over 50 countries through a mix of domestic prescription sales and international exports. The company employs roughly 6,975 people as ...

Catalysts

capex, margin expansion, geographic expansion

Growth guidance

No guidance

Management consistency

mixed